Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
José Ramírez homers as Guardians continue best start in franchise history with 4What is the Rwanda scheme? Your questions answeredHow major US stock indexes fared Tuesday, 4/23/2024Royal Navy names latest 7,400Defensemen injuries are already piling up early in the NHL playoffsBears GM Ryan Poles says 'tune in on Thursday' for No. 1 overall pick at the NFL draftFather rescued from migrant boat tragedy in Channel 'watched fourTurkish dental surgeon screwed tooth implant into father's BRAIN cavity in horrific blunderFather rescued from migrant boat tragedy in Channel 'watched fourSix winners of the Mail's Inspirational Women Awards are honoured in glittering ceremony in London
2.5494s , 6498.75 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,World Weaver news portal